These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33162175)

  • 21. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
    MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
    J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma.
    Popp FC; Capino I; Bartels J; Damanakis A; Li J; Datta RR; Löser H; Zhao Y; Quaas A; Lohneis P; Bruns CJ; On Behalf Of The Pancalyze Study Group
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34072549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
    Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
    J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
    Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
    Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion.
    Liu M; Li Z; Yao W; Zeng X; Wang L; Cheng J; Ma B; Zhang R; Min W; Wang H
    Mol Med Rep; 2020 Jan; 21(1):445-453. PubMed ID: 31746428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of human glioma-associated co-inhibitory immune checkpoints in glioma microenvironment and peripheral blood.
    Shen S; Wu Q; Liu J; Wu L; Zhang R; Uemura Y; Yu X; Chen L; Liu T
    Int J Immunopathol Pharmacol; 2021; 35():20587384211056505. PubMed ID: 34923867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
    Sue-A-Quan R; Patel PG; Shakfa N; Nyi MN; Afriyie-Asante A; Kang EY; Köbel M; Koti M
    Gynecol Oncol; 2021 Aug; 162(2):421-430. PubMed ID: 34088514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
    Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
    Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
    Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
    Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
    [No Abstract]   [Full Text] [Related]  

  • 30. Immune checkpoints as potential theragnostic biomarkers for epithelial ovarian cancer.
    Habel A; Weili X; Hadj Ahmed M; Stayoussef M; Bouaziz H; Ayadi M; Mezlini A; Larbi A; Yaacoubi-Loueslati B
    Int J Biol Markers; 2023 Dec; 38(3-4):203-213. PubMed ID: 37518940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
    Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
    Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer.
    Cherif B; Triki H; Charfi S; Bouzidi L; Kridis WB; Khanfir A; Chaabane K; Sellami-Boudawara T; Rebai A
    Sci Rep; 2021 Apr; 11(1):7550. PubMed ID: 33824367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages.
    Song M; Yeku OO; Rafiq S; Purdon T; Dong X; Zhu L; Zhang T; Wang H; Yu Z; Mai J; Shen H; Nixon B; Li M; Brentjens RJ; Ma X
    Nat Commun; 2020 Dec; 11(1):6298. PubMed ID: 33293516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
    Xu F; Liu T; Zhou Z; Zou C; Xu S
    Front Immunol; 2021; 12():749369. PubMed ID: 34745121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer.
    Høgdall E; Høgdall C; Vo T; Zhou W; Huang L; Marton M; Keefe SM; Busch-Sørensen M; Sørensen SM; Georgsen J; Mejlgaard E; Nedergaard L; Steiniche T
    Int J Gynecol Cancer; 2020 Jul; 30(7):1034-1042. PubMed ID: 32527769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
    Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
    Front Immunol; 2022; 13():974581. PubMed ID: 36159860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Impact of Tumor-Infiltrating Immune Cells on Efficacy of Neoadjuvant Chemotherapy in Patients with Advanced or Metastatic Ovarian Cancer: A Retrospective Study.
    Rao Q; Huang M; Guan M; Liu C; Wang L; Lin Z; Chen Q
    Med Sci Monit; 2024 Jul; 30():e943170. PubMed ID: 39018268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.
    Zhong YM; Yin K; Chen Y; Xie Z; Lv ZY; Yang JJ; Yang XN; Zhou Q; Wang BC; Zhong WZ; Gao LL; Zhou WB; Chen J; Tu HY; Liao RQ; Zhang DK; Zhang SL; Lu DX; Zheng HB; Zhang HH; Wu YL; Zhang XC
    Front Immunol; 2022; 13():951817. PubMed ID: 36263036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer.
    Kim JW; Nam KH; Ahn SH; Park DJ; Kim HH; Kim SH; Chang H; Lee JO; Kim YJ; Lee HS; Kim JH; Bang SM; Lee JS; Lee KW
    Gastric Cancer; 2016 Jan; 19(1):42-52. PubMed ID: 25424150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.